SRC and familial pancreatic carcinoma: Although there is minimal evidence in pancreatic cancer, research into other solid cancers including melanoma, sarcoma, colon and breast cancer demonstrates that Src‐inhibitors such as dasatinib have potent immunomodulatory functions 158, and consequently may present a promising adjunct to immunotherapy.